



Immune Modulating Therapeutics for Cancer Immunotherapy & Vaccination

Guest Editors:

Dr. Kuo-Ching Mei

Eshelman School of Pharmacy,
University of North Carolina at
Chapel Hill, Chapel Hill, NC
27599, USA

Dr. Tian Xia

David Geffen School of Medicine,
University of California, Los
Angeles, CA 94607, USA

Deadline for manuscript
submissions:

closed (31 August 2022)

Message from the Guest Editors

Dear Colleagues,

We are launching an exciting Special Issue on Immune Modulating Therapeutics for Cancer Immunotherapy & Vaccination. This Special Issue aims to collect original research and review articles on recent developments in the rapidly developing immune engineering field, focusing on immune-modulating therapeutics to empower cancer vaccination and immunotherapy. We are pleased to invite you to contribute to one of the broad topics that synergize the focus of this special issue, e.g., ways to increase cancer immunogenicity (with chemotherapeutics, PDT, radiation, or natural products etc.), novel vaccines to establish long-term anti-cancer immunity, strategies to overcome tumor immune suppression, CAR-T/NK therapeutics, novel antibody therapeutics, immune-modulating drug targets and drug discovery, methods to profile patient biopsy for personalized combinational immunotherapy, and other novel interventions, broadly defined. Thank you, and I look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com